"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Combination of Pembrolizumab (Keytruda) and lenvatinib (Lenvima)

17 Sep 2019 2:00 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to the combination of pembrolizumab (Keytruda; Merck) plus lenvatinib (Lenvima; Eisai) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software